Pharmion Doubles Vidaza Sales Guidance For Second Half 2004
This article was originally published in The Pink Sheet Daily
The company is raising its previous guidance of $20 mil.-$27 mil. due to greater than anticipated sales of the myelodysplastic syndromes treatment in the three months since launch.
You may also be interested in...
Approval comes more than a month before FDA’s June 29 action date for azacitidine.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles